TORONTO, June 23, 2015 (GLOBE NEWSWIRE) -- Profound Medical Corp. ("Profound" or the "Company") (TSX-V:PRN) is pleased to announce the results of the votes on the matters considered at its Annual Meeting of Shareholders that was held on June 22, 2015. A total of 14,581,000 common shares, representing 48.60% of the shares outstanding, were represented in person and by proxy at the meeting.

1. Election of Directors

At the Meeting, the shareholders of the Company elected all six nominees for the board of directors. Detailed results of the voting in respect of the election of directors are as follows:

2. Appointment of Auditors

At the Meeting, the shareholders of the Company appointed PricewaterhouseCoopers LLP to serve as the independent auditors for 2015.

About Profound Medical Corp.

Profound Medical is a medical device company that has developed a unique and minimally invasive treatment to ablate the prostate gland. Profound's novel technology combines MRI technology with ultrasound thermal energy that is delivered via a transurethral approach. This investigational method of prostate ablative therapy provides highly accurate and precise treatment within the prostate in a short time span, allowing for fast patient recovery. The potential of this technology is currently being assessed in clinical trials. For more information, visit profoundmedical.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.